Skip to main content
Premium Trial:

Request an Annual Quote

London Genetics, Astrimmune to Develop Biomarkers for Pancreatic Cancer Vaccine

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – London Genetics and Astrimmune today announced a collaboration to identify predictive biomarkers for a pancreatic cancer vaccine being developed by Astrimmune.

The collaboration, being supported with a grant from the UK East Midlands Development Agency, will seek to identify biomarkers predictive of clinical response.

In a statement, the two firms said that Astrimmune's vaccine induces antibody production against gastrin, a hormone which stimulates the growth of many types of gastrointestinal cancer. Different response rates have been observed in clinical trials of gastrin-blocking products, "and there is a clear need for biomarkers to help identify those patients mostly likely to benefit from Astrimmune's product," they said.

Financial and other terms of the deal were not disclosed.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.